CA
NZ
UK
AU
IND
US
• PM shares rose 1.35% today to $180.09, outperforming the broader market and consumer staples sector.
• The company's affiliate obtained new clinical laboratory licenses in Rhode Island and Pennsylvania.
• A federal judge granted a preliminary injunction blocking Colorado's price cap on Amgen's rheumatoid arthritis drug Enbrel.
• The company priced a $15 million registered direct equity offering to fund cancer program development.
• The stock's rally follows a blockbuster first-quarter 2026 earnings beat, with revenue of $19.8 billion, up 55.5% year over year.
• AstraZeneca entered a new collaboration with CSPC Pharmaceutical Group for siRNA-based drug candidates worth up to $570 million.
• The European Commission granted marketing authorization for Itvisma, a gene replacement therapy for spinal muscular atrophy.
• The move was driven by broader biotech sector momentum rather than company-specific news.
• A fresh £100 million buyback tranche launched July 1, running through July 21.
• The company secured dual positive CHMP opinions for RINVOQ in severe alopecia areata and non-segmental vitiligo.
Please wait processing your request...